Systematic review and meta-analyses of studies of glutamine supplementation in haematopoietic stem cell transplantation

Department of Haematology, Ward 16, Aberdeen Royal Infirmary, Aberdeen, AB25 2ZD, UK.
Bone marrow transplantation (Impact Factor: 3.47). 04/2009; 44(7):413-25. DOI: 10.1038/bmt.2009.41
Source: PubMed

ABSTRACT It is unclear whether supplemental glutamine is of benefit in haematopoietic stem cell transplantation (HSCT). We performed a systematic review and meta-analyses using Cochrane methodology. Seventeen randomized controlled trials (RCTs) were found. There was considerable heterogeneity between studies in terms of patient demographics and glutamine administration schedule. Many of the studies were small and scored poorly on methodological quality. Oral glutamine may reduce mucositis (average mucositis score: standard mean difference -0.38, 95% confidence interval (CI) -0.59 to -0.16) and days of opioids (mean difference -1.95 days, 95% CI -3.66 to -0.25) and GVHD (relative risk 0.42, 95% CI 0.21-0.85). Glutamine (i.v.) may reduce clinical infections (relative risk 0.75, 95% CI 0.58 to 0.97) and positive cultures (relative risk 0.72, 95% CI 0.57-0.91) but may also increase the risk of relapse (relative risk 2.91, 95% CI 1.34-6.29) but this is based on only two small studies. There was no effect of oral or i.v. glutamine on overall transplant-related mortality at day +100. In conclusion, there may be beneficial effects of glutamine in HSCT but larger, well-designed studies are required to confirm the beneficial effects and investigate possible adverse effects.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The combination of glutamine, fiber and oligosaccharides (GFO) is thought to be beneficial for alleviating gastrointestinal mucosal damage caused by chemotherapy. A commercial enteral supplementation product (GFO) enriched with these 3 components is available in Japan. We performed a retrospective study to test whether oral GFO decreased the severity of mucosal injury following hematopoietic stem cell transplantation (HSCT). Of 44 HSCT patients, 22 received GFO and 22 did not. Severity of diarrhea/mucositis, overall survival, weight loss, febrile illness/documented infection, intravenous hyperalimentation days/hospital days, engraftment, acute and chronic GVHD, and cumulative incidence of relapse were studied. Sex, age, performance status, diagnosis, disease status, and treatment variables were similar in both groups. There were fewer days of diarrhea grade 3-4 in patients receiving GFO than in those who did not (0.86 vs. 3.27 days); the same was true for days of mucositis grade 3-4 (3.86 vs. 6.00 days). Survival at day 100 was 100% in the GFO group, but only 77.3% for the patients not receiving GFO (p = 0.0091, log-rank test). Weight loss and the number of days of intravenous hyperalimentation were better in the GFO group (p < 0.001 and p = 0.0014, respectively). Although not significant, less gut bacterial translocation with Enterococcus species developed in the GFO group (p = 0.0728) than in the non-GFO group. Other outcomes were not affected. To the best of our knowledge, this is the first comparative clinical study of GFO supplementation to alleviate mucosal injury after allo-HSCT. We conclude that glutamine, fiber and oligosaccharide supplementation is an effective supportive therapy to decrease the severity of mucosal damage in HSCT.
    Case Reports in Oncology 01/2014; 7(3):692-699. DOI:10.1159/000368714
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Myeloablative allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a major procedure usually accompanied by multifactorial malnutrition, prompting the recommendation of systematic artificial nutritional support. Parenteral nutrition (PN) is usually administered during allo-HSCT, essentially for practical reasons. Recently published data suggest that enteral nutrition (EN), given as systematic artificial nutrition support, could decrease grade III–IV graft-versus-host disease (GVHD) and infectious events, which are associated with early toxicity after allo-HSCT and then have an impact on early transplant-related mortality (D100 mortality). Methods/Design We report on the NEPHA trial: an open-label, prospective, randomised, multi-centre study on two parallel groups, which has been designed to evaluate the effect of EN compared to PN on early toxicity after an allo-HSCT procedure. Two hundred forty patients treated with allo-HSCT for a haematological malignancy will be randomly assigned to two groups to receive either EN or PN. The primary endpoint will assess the effect of EN on D100 mortality. Secondary endpoints will compare EN and PN with regards to the main haematological, infectious and nutritional outcomes. Discussion The impacts of nutritional support should exceed the limits of nutritional status improvement: EN may directly reduce immunological and infectious events, as well as decrease early transplant-related morbidity and mortality. EN and PN need to be prospectively compared in order to assess their impacts and to provide treatment guidelines. (Clinical trials gov number: NCT01955772; registration: July 19th, 2013).
    Trials 04/2015; 16(1). DOI:10.1186/s13063-015-0663-8 · 2.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Im Jahr 2012 wurde eine Reihe von Arbeiten zur Frage der Prävention von Tumorerkrankungen mit Nahrungsergänzungsmitteln publiziert. Es gibt weiterhin keine Indikation für die Einnahme von Antioxidanzien in der gesunden Bevölkerung. Folsäure und Vitamin B12 könnten die Inzidenz von Tumorerkrankungen erhöhen. Vitamin D scheint sowohl in der primären Prävention wie in der Nachsorge eine hohe Bedeutung zu haben. Für Selen besteht sowohl bei Mangel als auch bei einem zu hohen Spiegel ein erhöhtes Risiko für eine Tumorerkrankung. Omega-3-Fettsäuren werden als antientzündlich wirkende Substanzen untersucht und könnten positive Effekte haben. Interaktionen sind nicht zu erwarten. Zu Granatapfelextrakt liegen 2 positive Studien beim Prostatakarzinom vor, beide enthalten jedoch keinen Kontrollarm ohne Extrakt. Zur Misteltherapie liegen weiterhin keine methodisch nicht anzuzweifelnden Studien vor, die eine positive Wirkung auf Überleben oder Nebenwirkungen der Tumortherapie beweisen. Inhaltsstoffe chinesischer Heilkräuter haben möglicherweise ein interessantes Potenzial in der Onkologie, über Neben- und Wechselwirkungen ist aber zu wenig bekannt, um ihren Einsatz außerhalb von Studien zu befürworten. Trotz umfangreicher Studien zur Akupunktur ist die Wirksamkeit bei Schmerzen, Fatigue und Xerostomie nicht bewiesen. Die Ergebnisse zu Übelkeit und Erbrechen werden in systematischen Übersichtsarbeiten positiv bewertet. Weiterhin liegt keine Studie vor, die die Wirkung der Homöopathie in der Onkologie belegt.
    Der Onkologe 11/2013; 19(11). DOI:10.1007/s00761-013-2541-x · 0.13 Impact Factor


Available from